文献速递淋巴瘤造血干细胞移植与细胞治疗

普瑞隆卡替奥仑赛(CD19/CD20 CAR-T细胞疗法)治疗复发/难治性B细胞非霍奇金淋巴瘤的1期试验

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
PubMed 文献 · Blood · 2025-01-01

这项1期开放标签研究评估了双特异性CD19/CD20 CAR-T细胞疗法普瑞隆卡替奥仑赛在复发/难治性B细胞非霍奇金淋巴瘤(R/R B-NHL)患者中的安全性和疗效。48例输注患者中44例为大B细胞淋巴瘤(LBCL),无患者发生剂量限制性毒性(DLT)。细胞因子释放综合征发生率为93.8%(仅1例3级),免疫效应细胞相关神经毒性综合征发生率为6.3%(无≥3级事件)。

要点

  • 48例R/R B-NHL患者输注普瑞隆卡替奥仑赛,44例为LBCL,无患者发生DLT。
  • 细胞因子释放综合征发生率93.8%(仅1例3级),免疫效应细胞相关神经毒性综合征发生率6.3%(无≥3级事件)。
  • 全部患者ORR 91.5%、CR率85.1%;LBCL患者ORR 90.7%、CR率86.0%。

核心结论

  • 普瑞隆卡替奥仑赛在R/R B-NHL患者中具有良好的安全性特征和高且持久的缓解,提示其可能成为R/R B-NHL有前景的治疗选择。

研究设计与样本

  • 1期开放标签研究,纳入CD19和/或CD20阳性的复发/难治性B细胞非霍奇金淋巴瘤(R/R B-NHL)患者。
  • 患者接受3天淋巴细胞清除(环磷酰胺300 mg/m2/天;氟达拉滨30 mg/m2/天),随后静脉输注普瑞隆卡替奥仑赛。
  • 共48例患者输注普瑞隆卡替奥仑赛,其中44例为大B细胞淋巴瘤(LBCL)。
  • 主要终点为剂量限制性毒性(DLT)和治疗中出现的不良事件(TEAE)的发生率及严重程度;次要终点包括总缓解率(ORR)、缓解持续时间(DOR)、无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 无患者发生DLT。
  • 细胞因子释放综合征发生率为93.8%,其中仅1例为3级。
  • 免疫效应细胞相关神经毒性综合征发生率为6.3%,无3级或以上事件。
  • 最常见的3级或以上TEAE为中性粒细胞减少(83.3%)和白细胞减少(50%)。
  • 全部患者ORR为91.5%、完全缓解(CR)率为85.1%;LBCL患者ORR为90.7%、CR率为86.0%。

关键数值与推荐

  • 中位随访30.0个月,中位DOR、PFS和OS均未达到。
  • Kaplan-Meier估计的2年DOR率、PFS率和OS率分别为66.0%、62.6%和76.5%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel. The primary end points were dose-limiting toxicity (DLT) and incidence and severity of treatment-emergent adverse events (TEAEs). Secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of the 48 patients infused prizlon-cel, 44 had large B-cell lymphoma (LBCL). No patient experienced DLT. Cytokine release syndrome occurred in 93.8% of the patients, with only 1 case of grade 3. Immune effector cell-associated neurotoxicity syndrome occurred in 6.3% of patients, with no grade 3 or higher events. The most common grade 3 or higher TEAEs were neutropenia (83.3%) and leukopenia (50%). The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow-up of 30.0 months, median DOR, PFS, and OS were all not reached. Kaplan-Meier estimate of 2-year DOR, PFS, and OS rates were 66.0%, 62.6%, and 76.5%, respectively. Prizlon-cel had a favorable safety profile and a high and durable response in patients with R/R B-NHL, suggesting a promising treatment option for patients with R/R B-NHL. These trials were registered at www.clinicaltrials.gov as #NCT04317885, #NCT04655677, #NCT04696432, and #NCT04693676.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yu W, Li P, Zhou L, et al. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2025. PMID: 39813680. doi:10.1182/blood.2024026401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。